A Study of XMT-1660 in Participants With Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Breast Cancer|Endometrial Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cavity Cancer
Interventions: DRUG: XMT-1660
Sponsor: Mersana Therapeutics